Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
Corrective press release regarding adverse events information from study AB09004
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer
Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
Signature of a 15.0 million financing deal with the European Investment Bank
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
Positive top-line Phase 3 results for oral masitinib in severe asthma
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma